D
David Sheridan
Researcher at University of Plymouth
Publications - 62
Citations - 4401
David Sheridan is an academic researcher from University of Plymouth. The author has contributed to research in topics: Hepatitis C virus & Hepatitis C. The author has an hindex of 21, co-authored 54 publications receiving 3540 citations. Previous affiliations of David Sheridan include Newcastle University & University of Sydney.
Papers
More filters
Journal ArticleDOI
IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy
Vijayaprakash Suppiah,Max Moldovan,Golo Ahlenstiel,Thomas Berg,Martin Weltman,Maria Lorena Abate,Margaret F. Bassendine,Ulrich Spengler,Gregory J. Dore,Gregory J. Dore,Elizabeth E. Powell,Elizabeth E. Powell,Stephen M. Riordan,David Sheridan,Antonina Smedile,Vincenzo Fragomeli,Tobias Müller,Melanie Bahlo,Graeme J. Stewart,David R. Booth,Jacob George +20 more
TL;DR: The data suggest that host genetics may be useful for the prediction of drug response, and they also support the investigation of the role of IL28B in the treatment of HCV and in other diseases treated with IFN-α.
Journal ArticleDOI
Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease
Peter J Eddowes,Magali Sasso,Michael Allison,Emmanouil Tsochatzis,Quentin M. Anstee,David Sheridan,Indra Neil Guha,Jeremy F. L. Cobbold,Jonathan J Deeks,Valérie Paradis,Pierre Bedossa,Philip N. Newsome,Philip N. Newsome +12 more
TL;DR: In a prospective analysis of patients with NAFLD, FibroScan vibration-controlled transient elastography controlled attenuation parameter (CAP) and liver stiffness measurement (LSMs) found to be effective in assessing liver steatosis and fibrosis, respectively, with AUROC values ranging from 0.70 to 0.89.
Journal ArticleDOI
FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study.
Philip N. Newsome,Philip N. Newsome,Magali Sasso,Jonathan J Deeks,Jonathan J Deeks,Angelo H. Paredes,Jérôme Boursier,Wah-Kheong Chan,Yusuf Yilmaz,Sébastien Czernichow,Ming-Hua Zheng,Ming-Hua Zheng,Vincent Wai-Sun Wong,Michael Allison,Emmanuel Tsochatzis,Quentin M. Anstee,David Sheridan,Peter J Eddowes,Indra Neil Guha,Jeremy F. L. Cobbold,Valérie Paradis,Pierre Bedossa,Véronique Miette,Céline Fournier-Poizat,Laurent Sandrin,Stephen A. Harrison +25 more
TL;DR: The FAST score provides an efficient way to non-invasively identify patients at risk of progressive NASH for clinical trials or treatments when they become available, and thereby reduce unnecessary liver biopsy in patients unlikely to have significant disease.
Journal ArticleDOI
IL28B, HLA-C and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a european cohort: A cross-sectional study
Vijayaprakash Suppiah,Silvana Gaudieri,Nicola J. Armstrong,Kate S. O'Connor,Thomas Berg,Martin Weltman,Maria Lorena Abate,Ulrich Spengler,Margaret F. Bassendine,Gregory J. Dore,Gregory J. Dore,William L. Irving,Elizabeth E. Powell,Elizabeth E. Powell,Margaret Hellard,Stephen M. Riordan,Gail V. Matthews,Gail V. Matthews,David Sheridan,Jacob Nattermann,Antonina Smedile,Tobias Müller,Emma Hammond,David S. Dunn,Francesco Negro,Pierre-Yves Bochud,Simon Mallal,Golo Ahlenstiel,Graeme J. Stewart,Jacob George,David R. Booth +30 more
TL;DR: Genotyping hepatitis C patients for the IL28B, HLA-C, and KIR genes improves the ability to predict whether or not patients will respond to antiviral treatment.
Journal ArticleDOI
Interferon-λ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease
Mohammed Eslam,Ahmed M. Hashem,Reynold Leung,Manuel Romero-Gómez,Thomas Berg,Gregory J. Dore,Henry L.K Chan,William L. Irving,David Sheridan,Maria Lorena Abate,Leon A. Adams,Alessandra Mangia,Martin Weltman,Elisabetta Bugianesi,Ulrich Spengler,Olfat G. Shaker,Janett Fischer,Lindsay Mollison,Wendy Cheng,Elizabeth E. Powell,Jacob Nattermann,Stephen M. Riordan,Duncan McLeod,Nicola J. Armstrong,Mark W. Douglas,Christopher Liddle,David R. Booth,Jacob George,Golo Ahlenstiel,Javier Ampuero,Margaret Bassendine,Vincent Wai-Sun Wong,Chiara Rosso,Rose White,Lavinia Mezzabotta,Vijayaprakash Suppiah,M. Michalk,Barbara Malik,Gail V. Matthews,Tanya L. Applegate,Jason Grebely,Vincenzo Fragomeli,Julie R. Jonsson,Rosanna Santaro +43 more
TL;DR: It is demonstrated that a single-nucleotide polymorphism (rs12979860) in the intronic region of interferon-λ4 (IFNL4) is a strong predictor of fibrosis in an aetiology-independent manner and is maximal in young females, especially those with HCV genotype 3.